Agreed. He has more big losers than big winners.
However, the one thing I will point to in our favor, is that they have COMPLETE control of Amarin, unlike most of their other investments, where they just have/had "influence".
The one other thing I will point to is 2021-2025 was one of the worst periods for biotech, which we can't really ignore. Prior to that, BP's were buying startups like expensive candy.
Market Data 
Markets 
AI
